Biogen Idec Presents 2012 Strategic Priorities at 30th Annual J.P. Morgan ... MarketWatch (press release) Continuing to advance the daclizumab Phase 3 program in MS. -- Drive innovation and grow early-stage pipeline by: -- Building world-class scientific teams in its core therapeutic areas. -- Advancing the company's internal early-stage pipeline programs. ... Biogen Idec Presents 2012 Strategic Priorities At 30th Annual J.P. Morgan ... |
